<div id="readability-page-1"><p>CeriBell, Inc. (NASDAQ:CBLL - Get Free Report) CEO Xingjuan Chao sold 39,000 shares of CeriBell stock in a transaction dated Monday, April 6th. The stock was sold at an average price of $18.40, for a total value of $717,600.00. Following the transaction, the chief executive officer owned 850,347 shares of the company's stock, valued at $15,646,384.80. The trade was a 4.39% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.</p><p>Xingjuan Chao also recently made the following trade(s): </p><ul><li>On Tuesday, March 3rd, Xingjuan Chao sold 39,000 shares of CeriBell stock. The stock was sold at an average price of $17.45, for a total value of $680,550.00. </li><li>On Monday, February 23rd, Xingjuan Chao sold 2,084 shares of CeriBell stock. The stock was sold at an average price of $19.79, for a total value of $41,242.36. </li></ul><h2>CeriBell Stock Performance</h2><p>CBLL stock traded up $0.78 during mid-day trading on Wednesday, hitting $18.65. 106,877 shares of the company were exchanged, compared to its average volume of 326,328. The business has a 50 day simple moving average of $19.15 and a 200-day simple moving average of $17.57. The company has a current ratio of 9.73, a quick ratio of 9.35 and a debt-to-equity ratio of 0.13. The stock has a market capitalization of $701.85 million, a PE ratio of -12.75 and a beta of 0.94. CeriBell, Inc. has a 1-year low of $10.01 and a 1-year high of $24.33. </p><p>CeriBell (NASDAQ:CBLL - Get Free Report) last issued its quarterly earnings data on Tuesday, February 24th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.43) by $0.07. CeriBell had a negative net margin of 59.97% and a negative return on equity of 31.77%. The firm had revenue of $24.78 million during the quarter, compared to the consensus estimate of $23.95 million.  On average, equities analysts forecast that  CeriBell, Inc. will post -2.46 earnings per share for the current year. </p><h2>Institutional Trading of CeriBell</h2><p>Institutional investors have recently bought and sold shares of the company. Caitong International Asset Management Co. Ltd raised its holdings in shares of  CeriBell by 3,971.0% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company's stock valued at $28,000 after purchasing an additional 1,231 shares during the period.  CWM LLC raised its holdings in shares of  CeriBell by 1,178.5% during the fourth quarter. CWM LLC now owns 1,841 shares of the company's stock valued at $40,000 after purchasing an additional 1,697 shares during the period.  Tower Research Capital LLC TRC raised its holdings in shares of  CeriBell by 353.8% during the second quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company's stock valued at $43,000 after purchasing an additional 1,801 shares during the period.  Larson Financial Group LLC raised its holdings in shares of  CeriBell by 1,403.1% during the fourth quarter. Larson Financial Group LLC now owns 2,871 shares of the company's stock valued at $63,000 after purchasing an additional 2,680 shares during the period.  Finally, Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of  CeriBell during the third quarter valued at about $33,000. </p><h2>Wall Street Analysts Forecast Growth</h2><p>A number of research firms have weighed in on CBLL. Canaccord Genuity Group boosted their target price on shares of CeriBell from $29.00 to $30.00 and gave the stock a &#34;buy&#34; rating in a research note on Wednesday, December 17th. Weiss Ratings  reaffirmed a &#34;sell (d-)&#34; rating on shares of CeriBell in a research note on Monday. TD Cowen  reaffirmed a &#34;buy&#34; rating on shares of CeriBell in a research note on Tuesday, December 9th. Finally, BTIG Research  reaffirmed a &#34;buy&#34; rating and set a $30.00 target price on shares of CeriBell in a research note on Wednesday, January 28th. One research analyst  has rated the stock with a Strong Buy rating, four have assigned  a Buy rating and one  has assigned  a Sell rating to the stock. According to MarketBeat.com, the company  has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $23.20.</p><p><b>Read Our Latest Stock Report on CeriBell</b></p><h2>CeriBell Company Profile</h2> (Get Free Report)<p>CeriBell Corp <span>NASDAQ: CBLL<span></span></span> is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell's solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.  </p><p>The company's product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than CeriBell</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0JMTA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0JMTA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in CeriBell Right Now?</h2><p>Before you consider CeriBell, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CeriBell wasn't on the list.</p><p>While CeriBell currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

CBLL

<p>CeriBell, Inc. CEO Xingjuan Chao sold 39,000 shares of the company's stock at an average price of $18.40, totaling $717,600. This sale reduced Chao's holdings by 4.39%, leaving 850,347 shares valued at approximately $15.65 million. The transaction was made under a Rule 10b5-1 trading plan and disclosed to the SEC. CeriBell's stock recently traded at $18.65, with a market cap of $701.85 million and a PE ratio of -12.75. Analysts have mixed ratings on the stock, with a consensus rating of "Moderate Buy" and an average target price of $23.20.</p>

Xingjuan Chao Sells 39,000 Shares of CeriBell (NASDAQ:CBLL) Stock